GeneDx Holdings Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by GeneDx Holdings Corp. on June 14, 2023. The report was filed on June 20, 2023. The company is incorporated in Delaware and its Class A common stock trades on the Nasdaq Global Select Market under the symbol WGS.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
The primary material event reported is the outcome of the stockholder vote at the Annual Meeting. There were 25,590,152 shares of Class A common stock issued and outstanding on the record date of May 8, 2023. All proposals presented were approved by the stockholders.
Outlook, Risks, and Management Commentary
The filing does not contain management commentary on future outlook, specific risks, contingencies, or unusual items. It references the Definitive Proxy Statement on Schedule 14A filed on April 28, 2023, for detailed descriptions of the proposals.
Key Facts for Investors to Verify
- Director Elections: Katherine Stueland and Jason Ryan were elected as Class II directors for three-year terms expiring in 2026.
- Voting Results for Directors: Katherine Stueland received 9,759,969 votes for and 2,895,500 withheld. Jason Ryan received 9,049,659 votes for and 3,605,810 withheld.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
- Voting Results for Auditor: 17,113,504 votes for, 24,127 votes against, and 3,783 abstentions.
- Share Count: 25,590,152 shares were outstanding on the record date.